Skip to main content

Advertisement

Log in

Changed Substance Use After Psychedelic Experiences Among Individuals in Canada

  • Original Article
  • Published:
International Journal of Mental Health and Addiction Aims and scope Submit manuscript

Abstract

We conducted a cross-sectional online survey of adults (n = 1639; 56.3% women) self-reporting past or current psychedelic use. We investigated whether psychedelic use was associated with self-reported changes in the use of other substances. Participants reported substantial changes, with 43.8% (n = 651/1488) decreasing or ceasing alcohol use, 42.5% (n = 272/640) ceasing or decreasing antidepressant use, and 42.4% (n = 200/471) decreasing or ceasing cocaine use. The highest rates of increased use were for cannabis (10.9%; n = 151/1383) and tobacco products (9.3%; n = 60/646). The most common reasons for substance use reductions were feeling more connected with self (73%; n = 632), nature (55%; n = 476), and others (54.6%; n = 473), as well as feeling less anxious or depressed (59.4%; n = 514). Factors associated with reduction in any substance use included motivation to treat a medical condition, number of psychedelics used, younger age, and using both microdoses and macrodoses. This real-world evidence should be rigorously investigated in future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Download references

Acknowledgements

The authors would like to thank all the participants in this study for taking the time to fill up our survey, and MAPS PBC, SABI Mind, and Psygen for co-sponsoring the Canadian Psychedelic Survey.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kevin F. Boehnke.

Ethics declarations

Ethical Approval

The study was co-sponsored by SABI Mind, the Multidisciplinary Association of Psychedelic Studies Public Benefits Corp. (MAPS PBC), and Psygen.

Ethics and Consent

The survey was ethics reviewed by Advarra (protocol # Pro00059863).

Consent to Participate

Online informed consent was obtained from all the study participants.

Competing Interests

Dr. Boehnke has received grant funding from Tryp Therapeutics and Algae Sciences. He sits on a Data Safety and Monitoring Committee (unpaid) for Vireo Health. Dr. Boehnke’s effort on this publication was partially supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K01DA049219 (KFB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Philippe Lucas PhD is President of SABI Mind, one of the co-sponsors of this study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boehnke, K.F., Kruger, D.J. & Lucas, P. Changed Substance Use After Psychedelic Experiences Among Individuals in Canada. Int J Ment Health Addiction 22, 842–853 (2024). https://doi.org/10.1007/s11469-023-01085-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11469-023-01085-z

Keywords

Navigation